Abstract
Introduction
The aim of the current study was to evaluate the usefulness of maximum standardized uptake value (SUVmax) in 2-deoxy-2-F18-fluoro-d-glucose positron emission tomography combined with computed tomography (18F-FDG-PET/CT) for preoperative differential diagnosis between benign and malignant bone tumors.
Materials and methods
Seventy-nine patients with bone tumors were examined by FDG-PET prior to histopathological diagnosis. The SUVmax was calculated and compared between benign and malignant lesions, and among different histopathological subgroups, to identify false-positive histological subtypes.
Results
There was a statistically significant difference in the SUVmax of benign (3.7 ± 3.3; n = 17) and malignant (5.3 ± 3.3; n = 62) bone tumors. However, receiver operating characteristic curve analysis revealed the poor accuracy of this distinction. The cut-off value was determined to be 2.6, while the value of sensitivity and specificity was calculated to be 74.2 and 64.7 %, respectively. Giant cell tumor of bone (9.0 ± 2.0; n = 5) displayed a higher SUVmax than osteosarcoma (4.2 ± 2.3; n = 18). Immunohistochemical analysis demonstrated that markers of these cancers, hexokinase-2 (HK-2) and glucose transporter type 1 (GLUT-1), supported our findings.
Conclusion
The poor accuracy of SUVmax in 18F-FDG-PET/CT in distinguishing malignant from benign bone tumors was confirmed; some benign bone tumors showed high FDG uptake. Giant cell tumor of bone was a major false-positive histopathological subtype of bone tumors, showing high FDG accumulation. HK-2 contributed significantly to FDG uptake, whereas GLUT-1 appeared to play no role in FDG uptake in giant cell tumor of bone.
Similar content being viewed by others
References
Kern KA, Brunetti A, Norton JA, Chang AE, Malawer M, Lack E et al (1988) Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 29:181–186
Aoki J, Endo K, Watanabe H, Shinozaki T, Yanagawa T, Ahmed AR et al (2003) FDG-PET for evaluating musculoskeletal tumors: a review. J Orthop Sci 8:435–441
Aoki J, Watanabe H, Shinozaki T, Takagishi K, Ishijima H, Oya N et al (2001) FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 219:774–777
Feldman F, van Heertum R, Manos C (2003) 18FDG PET scanning of benign and malignant musculoskeletal lesions. Skeletal Radiol 32:201–208
Charest M, Hickeson M, Lisbona R, Novales-Diaz JA, Derbekyan V, Turcotte RE (2009) FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. Eur J Nucl Med Mol Imaging 36:1944–1951
Benz MR, Dry SM, Eilber FC, Allen-Auerbach MS, Tap WD, Elashoff D et al (2010) Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET. J Nucl Med 51:1174–1181
Folpe AL, Lyles RH, Sprouse JT, Conrad EU 3rd, Eary JF (2000) (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 6:1279–1287
Eary JF, Conrad EU, Bruckner JD, Folpe A, Hunt KJ, Mankoff DA et al (1998) Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 4:1215–1220
Eftekhari F (2009) Imaging assessment of osteosarcoma in childhood and adolescence: diagnosis, staging, and evaluating response to chemotherapy. Cancer Treat Res 152:33–62
Cheon GJ, Kim MS, Lee JA, Lee SY, Cho WH, Song WS et al (2009) Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI. J Nucl Med 50:1435–1440
Dutour A, Decouvelaere AV, Monteil J, Duclos ME, Roualdes O, Rousseau R et al (2009) 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model. J Nucl Med 50:1533–1540
Watanabe H, Shinozaki T, Yanagawa T, Aoki J, Tokunaga M, Inoue T et al (2000) Glucose metabolic analysis of musculoskeletal tumours using 18fluorine-FDG PET as an aid to preoperative planning. J Bone Joint Surg Br 82:760–767
Hawkins DS, Conrad EU III, Butrynski JE, Schuetze SM, Eary JF (2009) [F-18]-fluorodeoxy-d-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer 115:3519–3525
Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Elashoff D et al (2009) FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res 15:2856–2863
Sato J, Yanagawa T, Dobashi Y, Yamaji T, Takagishi K, Watanabe H (2008) Prognostic significance of 18F-FDG uptake in primary osteosarcoma after but not before chemotherapy: a possible association with autocrine motility factor/phosphoglucose isomerase expression. Clin Exp Metastasis 25:427–435
Adler LP, Blair HF, Makley JT, Williams RP, Joyce MJ, Leisure G et al (1991) Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 32:1508–1512
Dehdashti F, Siegel BA, Griffeth LK, Fusselman MJ, Trask DD, McGuire AH et al (1996) Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-d-glucose. Radiology 200:243–247
Aoki J, Watanabe H, Shinozaki T, Takagishi K, Tokunaga M, Koyama Y et al (2003) FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses. Skeletal Radiol 32:133–138
Hamada K, Tomita Y, Qiu Y, Zhang B, Ueda T, Myoui A et al (2008) 18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase 2. Ann Nucl Med 22:699–705
Hamada K, Ueda T, Tomita Y, Higuchi I, Inoue A, Tamai N et al (2006) False positive 18F-FDG PET in an ischial chondroblastoma; an analysis of glucose transporter 1 and hexokinase II expression. Skeletal Radiol 35:306–310
Bischoff M, Bischoff G, Buck A, von Baer A, Pauls S, Scheffold F et al (2010) Integrated FDG-PET-CT: its role in the assessment of bone and soft tissue tumors. Arch Orthop Trauma Surg 130:819–827
Mueckler M (1994) Facilitative glucose transporters. Eur J Biochem 219:713–725
Bell GI, Kayano T, Buse JB, Burant CF, Takeda J, Lin D et al (1990) Molecular biology of mammalian glucose transporters. Diabetes Care 13:198–208
Paudyal B, Oriuchi N, Paudyal P, Higuchi T, Nakajima T, Endo K (2008) Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]-2-fluro-2-deoxy-d-glucose positron emission tomography. Cancer Sci 99:260–266
Fonteyne P, Casneuf V, Pauwels P, Van Damme N, Peeters M, Dierckx R et al (2009) Expression of hexokinases and glucose transporters in treated and untreated oesophageal adenocarcinoma. Histol Histopathol 24:971–977
Brown RS, Goodman TM, Zasadny KR, Greenson JK, Wahl RL (2002) Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol 29:443–453
Campanacci M, Baldini N, Boriani S, Sudanese A (1987) J Bone Joint Surg Am 69:106–114
Reid R, Banerjee SS, Sciot R (2001) Giant cell tumor. In: Fletchcher CDM, Unni KK, Mertens F (eds) World Health Organization classification of tumors: pathology and genetics; tumors of soft tissue and bone. International Agency for Research on Cancer, Lyon, pp 310–312
Balke M, Schremper L, Gebert C, Ahrens H, Streitbuerger A, Koehler G et al (2008) Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol 134:969–978
Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH (2011) Recurrent giant cell tumor of long bones: analysis of surgical management. Clin Orthop Relat Res 469:1181–1187
Kivioja AH, Blomqvist C, Hietaniemi K, Trovik C, Walloe A, Bauer HC et al (2008) Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop 79:86–93
Viswanathan S, Jambhekar NA (2010) Metastatic giant cell tumor of bone: are there associated factors and best treatment modalities? Clin Orthop Relat Res 468:827–833
Dominkus M, Ruggieri P, Bertoni F, Briccoli A, Picci P, Rocca M et al (2006) Histologically verified lung metastases in benign giant cell tumours—14 cases from a single institution. Int Orthop 30:499–504
Abdel-Nabi H, Doerr RJ, Lamonica DM, Cronin VR, Galantowicz PJ, Carbone GM et al (1998) Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 206:755–760
Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G et al (2008) Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 26:4746–4751
Christensen JD, Colby TV, Patz EF Jr (2010) Correlation of [18F]-2-fluoro-deoxy-d-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer. Cancer 116:4095–4102
Noguchi Y, Marat D, Saito A, Yoshikawa T, Doi C, Fukuzawa K et al (1999) Expression of facilitative glucose transporters in gastric tumors. Hepatogastroenterol 46:2683–2689
Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, Nakamoto Y et al (2005) [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 7:369–379
Paudyal B, Paudyal P, Oriuchi N, Tsushima Y, Nakajima T, Endo K (2008) Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma. Int J Oncol 33:1047–1054
Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT (1997) Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 80:1046–1051
Ahrens WA, Ridenour RV 3rd, Caron BL, Miller DV, Folpe AL (2008) GLUT-1 expression in mesenchymal tumors: an immunohistochemical study of 247 soft tissue and bone neoplasms. Hum Pathol 39:1519–1526
Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Hasegawa T (2006) Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging 33:683–691
Endo M, Tateishi U, Seki K, Yamaguchi U, Nakatani F, Kawai A et al (2007) Prognostic implications of glucose transporter protein-1 (glut-1) overexpression in bone and soft-tissue sarcomas. Jpn J Clin Oncol 37:955–960
Cifuentes M, García MA, Arrabal PM, Martínez F, Yañez MJ, Jara N et al (2011) Insulin regulates GLUT1-mediated glucose transport in MG-63 human osteosarcoma cells. J Cell Physiol 226:1425–1432
Robey RB, Hay N (2005) Mitochondrial hexokinases: guardians of the mitochondria. Cell Cycle 4:654–658
Mathupala SP, Rempel A, Pedersen PL (1997) Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 29:339–343
Ito T, Noguchi Y, Satoh S, Hayashi H, Inayama Y, Kitamura H (1998) Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol 11:437–443
Shim HK, Lee WW, Park SY, Kim H, So Y, Kim SE (2009) Expressions of glucose transporter Types 1 and 3 and hexokinase-II in diffuse large B-cell lymphoma and other B-cell non-Hodgkin’s lymphomas. Nucl Med Biol 36:191–197
Bakheet SM, Saleem M, Powe J, Al-Amro A, Larsson SG, Mahassin Z (2000) F-18 fluorodeoxyglucose chest uptake in lung inflammation and infection. Clin Nucl Med 25:273–278
Acknowledgments
We thank Dr. Wakasa for histopathological diagnosis of bone tumors, and also thank Dr Nishikubo for examination of 18F-FDG-PET/CT data.
Conflict of interest
The authors declare they have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hoshi, M., Takada, J., Oebisu, N. et al. Overexpression of hexokinase-2 in giant cell tumor of bone is associated with false positive in bone tumor on FDG-PET/CT. Arch Orthop Trauma Surg 132, 1561–1568 (2012). https://doi.org/10.1007/s00402-012-1588-2
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00402-012-1588-2